重组人干扰素α1b雾化吸入治疗儿童上呼吸道病毒感染及预防儿童上呼吸道病毒感染诱发毛细支气管炎效果研究  

Clinical Effect of Aerosol Inhalation of Recombinant Human Interferon α1b on Children with Viral Upper Respiratory Tract Infection and Prevention of Capillary Bronchitis Induced by Viral Upper Respiratory Tract Infection

作　　者：刘连凤[1] 史军然[1] 薛红霞[2] 周秀敏[1] 高虹 薛宁宁 LIU Lian-feng;SHI Jun-ran;XUE Hong-xia;ZHOU Xiu-min;GAO Hong;XUE Ning-ning(Department of Pediatrics, the Maternal and Child Health Hospital of Shijiazhuang, Shijiazhuang 050051, China;Department of Pediatrics, the Third Hospital of Shijiazhuang, Shijiazhuang 050011, China)

机构地区：[1]石家庄市妇幼保健院儿科,石家庄050051 [2]石家庄市第三医院儿科,石家庄050000

出　　处：《临床误诊误治》2019年第5期24-29,共6页Clinical Misdiagnosis & Mistherapy

基　　金：河北省医学科学研究指导计划课题项目(20150885)

摘　　要：目的探讨重组人干扰素α1b雾化吸入治疗儿童上呼吸道病毒感染及预防儿童上呼吸道病毒感染诱发毛细支气管炎效果。方法选取有毛细支气管炎病史急性上呼吸道病毒感染患儿140例,按入院顺序交替分为观察组和对照组两组各70例。观察组在对症支持治疗基础上给予重组人干扰素α1b注射液雾化吸入,对照组在对症支持治疗基础上给予利巴韦林注射液雾化吸入,两组均治疗7 d。观察比较两组总病程、退热时间、咳嗽消失时间,上呼吸道病毒感染治疗效果及预防上呼吸道病毒感染发病7 d内诱发毛细支气管炎效果,治疗前后血清炎性因子水平及治疗过程中不良反应发生情况。结果观察组总病程、退热时间及咳嗽消失时间均短于对照组,差异有统计学意义(P<0.05)。治疗后,观察组总有效率为78.6%高于对照组总有效率61.4%;治疗7 d内,观察组毛细支气管炎发生率为15.7%低于对照组毛细支气管炎发生率35.7%,差异均具有统计学意义(P<0.05)。治疗前,两组血清炎性因子水平比较差异均无统计学意义(P>0.05)。治疗后,观察组和对照组血清肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)及C反应蛋白(CRP)水平均低于治疗前,观察组血清TNF-α、IL-6及CRP水平均低于对照组,差异具有统计学意义(P<0.05)。治疗过程中两组均未出现明显不良反应。结论重组人干扰素α1b注射液雾化吸入治疗儿童上呼吸道病毒感染及预防儿童上呼吸道病毒感染诱发毛细支气管炎效果优于利巴韦林注射液雾化吸入,且无明显不良反应。ObjectiveTo investigate and analyze the efficacy of aerosol inhalation of recombinant human interferon α1b (rh IFNα-1b) in the treatment of viral upper respiratory tract infection (URTI) and prevention of capillary bronchitis induced by URTI in children. MethodsA total of 140 patients with acute viral URTI who had a history of capillary bronchitis were selected as subjects. According to the order of admission, they were alternately divided into treatment group (n=70) and control group (n=70). The observation group was treated with rh IFNα-1b injection by aerosol inhalation on the basis of conventional treatment. Control group was treated with aerosol inhalation of ribavirin injection on the basis of conventional treatment. The course of treatment was 7 d. The total course of disease, duration of fever, time of cough disappearance, clinical effect of viral URTI and prevention of capillary bronchitis induced by viral URTI within 7 d were compared between the two groups. The serum inflammatory factors before and after treatment, and the incidence of adverse reactions during the treatment were observed. ResultsThe total course of disease, duration of fever, time of cough disappearance in the observation group were shorter than those in the control group, and the difference was statistically significant ( P <0.05). The total effective rate was 78.6% in the observation group, which was higher than that (61.4%) in the control group after treatment ( P <0.05). Within 7 d of treatment, the incidence rate of capillary bronchitis was 15.7% in the observation group, which was lower than that (35.7%) in the control group after treatment, and the difference was statistically significant ( P <0.05). Before treatment, no significant differences were found in tumor necrosis factor α(TNF-α), interleukin 6 (IL-6) or C-reactive protein (CRP) between the two groups ( P >0.05). After treatment, TNF-α, IL-6 and CRP in observation group and control group were lower than those before treatment ( P <0.01), and TNF-α, IL-6 and CRP i

关 键 词：重组人干扰素Α1B 上呼吸道感染 病毒 毛细支气管炎 

分 类 号：R511.7[医药卫生—内科学]